Developer docs
API playgroundTry for free, no card

Search company profiles

Mabwell Biotech

Full company profile

uuid0000ajs

Namestring
Mabwell Biotech
Legal namestring
Mabwell (Shanghai) Bioscience Co., Ltd. (迈威(上海)生物科技股份有限公司)
Websiteurl
mabwell.com
Company typeenum
Public
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
antibody drug development, oncology biologics, ADC therapeutics, biosimilar manufacturing, biopharmaceutical R&D
Industry6 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAHAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code4 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Drug Product Sales (Commercialized Products)
TypeHardware Sales
Description

Sales revenue from 4 commercialized products: MAILISHENG (albipagrastim alfa / G-CSF), MAIWEIJIAN (denosumab biosimilar 120mg), MAILISHU (denosumab biosimilar 60mg), and JUNMAIKANG (adalimumab biosimilar). Recurring revenue from domestic China market and emerging markets via licensing partners.

mabwell.com
2International Out-licensing (License-out / NewCo)
TypeLicensing Royalties
Description

Upfront payments, milestone payments, and royalties from out-licensing novel drug candidates to international partners. Total deal value over US$1 billion including: DISC Medicine for 9MW3011 (up to US$412.5M), Calico Life Sciences for 9MW3811 (over US$600M), Aditum Bio/Kalexo Bio for 2MW7141, and Qilu Pharmaceutical for MAILISHENG in Greater China.

mabwell.com
3Emerging Market Commercialization Partnerships
TypeLicensing Royalties
Description

Revenue from licensing and commercialization agreements with regional pharma partners in 33+ countries for denosumab biosimilars, adalimumab biosimilar, and aflibercept biosimilar across ASEAN, MENA, South Asia, Latin America and Africa. Includes upfront fees, milestone payments and supply/profit-sharing.

mabwell.com
4Biosimilar International Supply and Royalty
TypeHardware Sales
Description

International supply of approved biosimilars with marketing authorization obtained in Pakistan and submitted in 8+ additional countries including Brazil, Saudi Arabia, Indonesia, Jordan, Egypt, Colombia, Ecuador, Morocco, Argentina, Thailand.

prnewswire.com
Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1MAILISHENG (迈粒生)
Description

Mabwell's first commercialized Class 1 innovative drug — Albipagrastim alfa for Injection, the first domestically launched long-acting G-CSF developed with albumin fusion technology; indicated for febrile neutropenia. Licensed to Qilu Pharmaceutical in Greater China.

mabwell.com
+4 more records
Core offering1 text field

Mabwell Biotech is an innovation-driven biopharmaceutical company that develops, manufactures, and commercializes therapeutic biologics across oncology, immunology, bone disorders, ophthalmology, hematology, and cardiovascular disease. Its portfolio comprises antibody-drug conjugates (ADCs), bispecific and trispecific antibodies, monoclonal antibodies, and biosimilars. The company has four commercialized products (MAILISHENG/albipagrastim alfa, MAIWEIJIAN/denosumab 120mg biosimilar, MAILISHU/denosumab 60mg biosimilar, JUNMAIKANG/adalimumab biosimilar) and 10+ clinical-stage candidates built on its proprietary IDDC™ ADC platform and T-cell Engager bispecific platform.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Mabwell Bioscience (迈威生物, 688062.SH, 02493.HK) operates as an innovation-driven biopharmaceutical company with full industry chain integration covering R&D, manufacturing, and commercialization. The company's product portfolio spans 16 high-priority candidates across oncology, immunology, bone disorders, ophthalmology, hematology, and cardiovascular disease, with 4 products commercially launched (迈粒生®/MAILISHENG, 迈卫健®/MAIWEIJIAN, 迈利舒®/MAILISHU, 君迈康®/JUNMAIKANG), 1 in NDA review, and 2 in pivotal Phase III trials. The pipeline centers on the proprietary IDDC™ ADC platform powering the core Nectin-4 ADC candidate 9MW2821 (Bulumtatug Fuvedotin), complemented by B7-H3 ADC 7MW3711, CDH17 ADC 7MW4911, and Trop-2 ADC 9MW2921, alongside bispecific TCE platform assets like 6MW5311 and monoclonal antibodies including anti-ST2 9MW1911, anti-TMPRSS6 9MW3011, and anti-IL-11 9MW3811. Mabwell operates biopharmaceutical manufacturing facilities in Taizhou (Jiangsu) and Shanghai (Jinshan) compliant with China NMPA, U.S. FDA, and EU EMA GMP standards.

Product and service10 records
1MAILISHENG (迈粒生) - Albipagrastim alfa for Injection
CategoryCommercialized Biologic Drug (Class 1 Innovative Drug)
Description

First Class 1 innovative drug commercially launched by Mabwell. First launched novel granulocyte colony-stimulating factor (G-CSF) developed with albumin long-acting fusion technology in China. Indicated to decrease the incidence of infection manifested by febrile neutropenia in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. Uses Pichia pastoris expression system for production. Licensed to Qilu Pharmaceutical for Greater China.

2MAIWEIJIAN (迈卫健) - Denosumab Biosimilar 120mg (9MW0321)
CategoryCommercialized Biosimilar Drug
Description

One of the first-tier approved biosimilars of Xgeva® (120mg) in China and the first approved denosumab biosimilar in Pakistan. Indicated for giant cell tumor of bone, bone metastases from solid tumors, and multiple myeloma. Works by binding RANKL to inhibit OPG/RANKL/RANK signaling pathway activation, suppressing tumor growth and reducing bone destruction.

3MAILISHU (迈利舒) - Denosumab Biosimilar 60mg (9MW0311)
CategoryCommercialized Biosimilar Drug
Description

Second Prolia® biosimilar in China and first in Pakistan. Used to treat bone loss (osteoporosis) in postmenopausal women at high risk of fractures. Acts as a RANKL inhibitor to prevent osteoclastic-mediated bone resorption. Approved in China and Pakistan.

4JUNMAIKANG (君迈康) - Adalimumab Biosimilar (9MW0113)
CategoryCommercialized Biosimilar Drug
Description

Recombinant humanized anti-TNF-α monoclonal antibody injection jointly developed with Junshi Biosciences. Approved by NMPA in China for 8 indications including rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn's disease. Also approved in Indonesia as the first China-developed biosimilar to gain approval in that market.

59MW2821 (Bulumtatug Fuvedotin) - Nectin-4 ADC
CategoryPipeline Clinical-Stage Drug Candidate (Core ADC Product)
Description

Next-generation Nectin-4 targeting antibody-drug conjugate independently developed by Mabwell using the IDDC™ platform. First clinical-stage Nectin-4 ADC candidate in China and first to publish clinical efficacy data in cervical, esophageal, and breast cancers. Currently in four pivotal Phase III trials for urothelial carcinoma, cervical cancer, triple-negative breast cancer, and esophageal cancer.

69MW1911 - Anti-ST2 Monoclonal Antibody
CategoryPipeline Clinical-Stage Drug Candidate
Description

Innovative humanized monoclonal antibody developed by Mabwell based on the B-lymphocyte screening platform. First anti-ST2 antibody developed by a Chinese company to enter clinical trials. Binds ST2 receptor with high affinity to block IL-33/ST2 signaling pathway, inhibiting inflammatory reactions. Indicated for chronic obstructive pulmonary disease (COPD), asthma, and atopic dermatitis. Phase IIa results showed >30% reduction in moderate-to-severe COPD exacerbations and >40% reduction in severe exacerbations.

79MW3011 (DISC-3405) - Anti-TMPRSS6 Monoclonal Antibody
CategoryPipeline Clinical-Stage Drug Candidate
Description

Anti-TMPRSS6 antibody developed by Mabwell's Innovation R&D Center in San Diego, U.S. First anti-TMPRSS6 antibody in China and top tier globally. Regulates iron homeostasis by upregulating hepcidin expression. Indications include polycythemia vera, β-thalassemia, and iron overload disorders. Granted FDA Fast Track Designation and Orphan Drug Designation. Licensed to DISC Medicine (NASDAQ: IRON) for all regions except Greater China and Southeast Asia for up to US$412.5 million in milestones.

89MW3811 - Anti-IL-11 Monoclonal Antibody
CategoryPipeline Clinical-Stage Drug Candidate
Description

Innovative humanized monoclonal antibody against IL-11 (Interleukin-11) developed for fibrosis and oncology. First anti-IL-11 antibody to enter clinical trial in China and top tier globally. First IL-11-targeting therapeutic to enter clinical stage for pathological scarring worldwide. Also targeting idiopathic pulmonary fibrosis (IPF). Approved to initiate clinical study in China, Australia, and US. Long half-life exceeding one month. Licensed exclusively to Calico Life Sciences (Alphabet) for all regions except Greater China.

97MW3711 - B7-H3 ADC
CategoryPipeline Clinical-Stage Drug Candidate
Description

Novel B7-H3 targeting antibody-drug conjugate developed by Mabwell using the IDDC™ platform. Composed of innovative antibody molecule, novel linker, and novel topoisomerase I inhibitor payload (Mtoxin™). Granted FDA Orphan Drug Designation for small cell lung cancer. Has potential applications in lung cancer, sarcoma, prostate cancer, head and neck cancer, and esophageal cancer. Phase II clinical trial ongoing.

107MW4911 - CDH17 ADC
CategoryPipeline Clinical-Stage Drug Candidate
Description

ADC targeting cadherin-17 (CDH17) developed using Mabwell's proprietary IDDC™ antibody conjugation technology platform. Integrates high-specificity CDH17 monoclonal antibody with fast internalization characteristics, novel cleavable linker, and proprietary DNA topoisomerase I inhibitor MF-6 payload designed to overcome multidrug resistance. Homogeneous drug loading (DAR=4 ratio >95%) with stable plasma. IND cleared by both FDA and NMPA for advanced solid tumors and advanced colorectal/gastrointestinal cancers.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global biopharmaceutical company partnering with Daiichi Sankyo on ADC franchise (Enhertu, Datopotamab Deruxtecan). AstraZeneca's ADC commercial reach and global regulatory experience represent the competitive benchmark Mabwell's Nectin-4 ADC 9MW2821 must contend with in major oncology indications.

TypeBroad incumbent
Description

Global biotechnology company specializing in antibody therapeutics with proprietary DuoBody bispecific platform. Genmab's bispecific antibody technology and pipeline (including epcoritamab) are directly comparable to Mabwell's TCE bispecific platform approach and 6MW5311 program.

3Hansoh Pharmaceutical
TypeBroad incumbent
Description

Large Chinese innovative biopharmaceutical company with HKEX listing developing oncology, psychiatry, and infectious disease therapeutics. Hansoh operates a comparable full-industry-chain business model and competes for the same Chinese biopharma talent, capital, and commercial channels as Mabwell.

TypeBroad incumbent
Description

Large globally-operating Chinese biopharmaceutical company with HKEX and NASDAQ listings developing innovative oncology biologics including BRUKINSA (zanubrutinib). As a broad incumbent in the same Chinese innovative biopharma category, BeiGene's scale and global commercial infrastructure represent the standard Mabwell aspires to match.

TypeBroad incumbent
Description

Global pharmaceutical leader in antibody-drug conjugates, with DXd-ADC platform powering Enhertu (HER2) and Datopotamab Deruxtecan (Trop-2). Daiichi Sankyo/AstraZeneca represent the gold-standard ADC competitor that Mabwell's IDDC™ platform must differentiate against in oncology indications.

TypeDirect peer
Description

Leading Chinese innovative biopharmaceutical company developing oncology biologics including PD-1 inhibitors (sintilimab) and ADCs. Innovent operates a similar dual-listing model (HKEX, STAR Market) with comparable full-industry-chain R&D-to-commercialization structure and competes directly with Mabwell in China oncology biologics.

7Henlius
TypeDirect peer
Description

Chinese biopharmaceutical company focused on biosimilars and innovative oncology biologics with HKEX listing. Henlius launched multiple biosimilars (rituximab, trastuzumab, bevacizumab, adalimumab) similar to Mabwell's MAILISHU, MAIWEIJIAN, and JUNMAIKANG biosimilars, and operates a similar global emerging-market out-licensing model.

TypeDirect peer
Description

Co-developer of Mabwell's JUNMAIKANG adalimumab biosimilar and fellow Shanghai-based innovative biopharmaceutical company. Junshi has a comparable pipeline of innovative monoclonal antibodies and bispecifics, and was co-founded by Mabwell's President of R&D Dr. Wu Hai, providing direct operational and pipeline overlap.

TypeDirect peer
Description

Chinese biopharmaceutical company specializing in bispecific antibodies (e.g., cadonilimab, ivonescimab) with HKEX listing. Akeso's T-cell engagers and bispecific antibody platform are directly comparable to Mabwell's TCE bispecific platform and 6MW5311 program.

TypeDirect peer
Description

Chinese biopharmaceutical company with a directly comparable ADC and bispecific antibody pipeline. RemeGen's disitamab vedotin (RC48, Nectin-4 ADC) is the most direct competitor to Mabwell's 9MW2821, and RemeGen also operates in oncology biologics with self-developed ADC platform technology targeting similar indications (gastric, urothelial, breast).

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mabwell Biotech

Biopharmaceuticalsmabwell.com

Mabwell Biotech firmographics

Firmographics
Name
Mabwell Biotech
Legal name
Mabwell (Shanghai) Bioscience Co., Ltd. (迈威(上海)生物科技股份有限公司)
Website
https://mabwell.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Mabwell Biotech industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAHAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Antibody drug development
  • Oncology biologics
  • ADC therapeutics
  • Biosimilar manufacturing
  • Biopharmaceutical R&D

Where Mabwell Biotech is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Markets served

Mabwell Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Drug Product Sales (Commercialized Products): Sales revenue from 4 commercialized products: MAILISHENG (albipagrastim alfa / G-CSF), MAIWEIJIAN (denosumab biosimilar 120mg), MAILISHU (denosumab biosimilar 60mg), and JUNMAIKANG (adalimumab biosimilar). Recurring revenue from domestic China market and emerging markets via licensing partners.
  2. International Out-licensing (License-out / NewCo): Upfront payments, milestone payments, and royalties from out-licensing novel drug candidates to international partners. Total deal value over US$1 billion including: DISC Medicine for 9MW3011 (up to US$412.5M), Calico Life Sciences for 9MW3811 (over US$600M), Aditum Bio/Kalexo Bio for 2MW7141, and Qilu Pharmaceutical for MAILISHENG in Greater China.
  3. Emerging Market Commercialization Partnerships: Revenue from licensing and commercialization agreements with regional pharma partners in 33+ countries for denosumab biosimilars, adalimumab biosimilar, and aflibercept biosimilar across ASEAN, MENA, South Asia, Latin America and Africa. Includes upfront fees, milestone payments and supply/profit-sharing.
  4. Biosimilar International Supply and Royalty: International supply of approved biosimilars with marketing authorization obtained in Pakistan and submitted in 8+ additional countries including Brazil, Saudi Arabia, Indonesia, Jordan, Egypt, Colombia, Ecuador, Morocco, Argentina, Thailand.

Go-to-market motion1 record

Mabwell Biotech product offering

Product offering

Core offering

Mabwell Biotech is an innovation-driven biopharmaceutical company that develops, manufactures, and commercializes therapeutic biologics across oncology, immunology, bone disorders, ophthalmology, hematology, and cardiovascular disease. Its portfolio comprises antibody-drug conjugates (ADCs), bispecific and trispecific antibodies, monoclonal antibodies, and biosimilars. The company has four commercialized products (MAILISHENG/albipagrastim alfa, MAIWEIJIAN/denosumab 120mg biosimilar, MAILISHU/denosumab 60mg biosimilar, JUNMAIKANG/adalimumab biosimilar) and 10+ clinical-stage candidates built on its proprietary IDDC™ ADC platform and T-cell Engager bispecific platform.

Product overview

Mabwell Bioscience (迈威生物, 688062.SH, 02493.HK) operates as an innovation-driven biopharmaceutical company with full industry chain integration covering R&D, manufacturing, and commercialization. The company's product portfolio spans 16 high-priority candidates across oncology, immunology, bone disorders, ophthalmology, hematology, and cardiovascular disease, with 4 products commercially launched (迈粒生®/MAILISHENG, 迈卫健®/MAIWEIJIAN, 迈利舒®/MAILISHU, 君迈康®/JUNMAIKANG), 1 in NDA review, and 2 in pivotal Phase III trials. The pipeline centers on the proprietary IDDC™ ADC platform powering the core Nectin-4 ADC candidate 9MW2821 (Bulumtatug Fuvedotin), complemented by B7-H3 ADC 7MW3711, CDH17 ADC 7MW4911, and Trop-2 ADC 9MW2921, alongside bispecific TCE platform assets like 6MW5311 and monoclonal antibodies including anti-ST2 9MW1911, anti-TMPRSS6 9MW3011, and anti-IL-11 9MW3811. Mabwell operates biopharmaceutical manufacturing facilities in Taizhou (Jiangsu) and Shanghai (Jinshan) compliant with China NMPA, U.S. FDA, and EU EMA GMP standards.

Differentiator

Problem solved

Functional benefit

Brands

  • MAILISHENG (迈粒生): Mabwell's first commercialized Class 1 innovative drug — Albipagrastim alfa for Injection, the first domestically launched long-acting G-CSF developed with albumin fusion technology; indicated for febrile neutropenia. Licensed to Qilu Pharmaceutical in Greater China.
  • MAIWEIJIAN (迈卫健)
  • MAILISHU (迈利舒)
  • JUNMAIKANG (君迈康)
  • Myvision (迈威视)

Products and services

  • MAILISHENG (迈粒生) - Albipagrastim alfa for Injection First Class 1 innovative drug commercially launched by Mabwell. First launched novel granulocyte colony-stimulating factor (G-CSF) developed with albumin long-acting fusion technology in China. Indicated to decrease the incidence of infection manifested by febrile neutropenia in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. Uses Pichia pastoris expression system for production. Licensed to Qilu Pharmaceutical for Greater China.
  • MAIWEIJIAN (迈卫健) - Denosumab Biosimilar 120mg (9MW0321) One of the first-tier approved biosimilars of Xgeva® (120mg) in China and the first approved denosumab biosimilar in Pakistan. Indicated for giant cell tumor of bone, bone metastases from solid tumors, and multiple myeloma. Works by binding RANKL to inhibit OPG/RANKL/RANK signaling pathway activation, suppressing tumor growth and reducing bone destruction.
  • MAILISHU (迈利舒) - Denosumab Biosimilar 60mg (9MW0311) Second Prolia® biosimilar in China and first in Pakistan. Used to treat bone loss (osteoporosis) in postmenopausal women at high risk of fractures. Acts as a RANKL inhibitor to prevent osteoclastic-mediated bone resorption. Approved in China and Pakistan.
  • JUNMAIKANG (君迈康) - Adalimumab Biosimilar (9MW0113) Recombinant humanized anti-TNF-α monoclonal antibody injection jointly developed with Junshi Biosciences. Approved by NMPA in China for 8 indications including rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn's disease. Also approved in Indonesia as the first China-developed biosimilar to gain approval in that market.
  • 9MW2821 (Bulumtatug Fuvedotin) - Nectin-4 ADC Next-generation Nectin-4 targeting antibody-drug conjugate independently developed by Mabwell using the IDDC™ platform. First clinical-stage Nectin-4 ADC candidate in China and first to publish clinical efficacy data in cervical, esophageal, and breast cancers. Currently in four pivotal Phase III trials for urothelial carcinoma, cervical cancer, triple-negative breast cancer, and esophageal cancer.
  • 9MW1911 - Anti-ST2 Monoclonal Antibody Innovative humanized monoclonal antibody developed by Mabwell based on the B-lymphocyte screening platform. First anti-ST2 antibody developed by a Chinese company to enter clinical trials. Binds ST2 receptor with high affinity to block IL-33/ST2 signaling pathway, inhibiting inflammatory reactions. Indicated for chronic obstructive pulmonary disease (COPD), asthma, and atopic dermatitis. Phase IIa results showed >30% reduction in moderate-to-severe COPD exacerbations and >40% reduction in severe exacerbations.
  • 9MW3011 (DISC-3405) - Anti-TMPRSS6 Monoclonal Antibody Anti-TMPRSS6 antibody developed by Mabwell's Innovation R&D Center in San Diego, U.S. First anti-TMPRSS6 antibody in China and top tier globally. Regulates iron homeostasis by upregulating hepcidin expression. Indications include polycythemia vera, β-thalassemia, and iron overload disorders. Granted FDA Fast Track Designation and Orphan Drug Designation. Licensed to DISC Medicine (NASDAQ: IRON) for all regions except Greater China and Southeast Asia for up to US$412.5 million in milestones.
  • 9MW3811 - Anti-IL-11 Monoclonal Antibody Innovative humanized monoclonal antibody against IL-11 (Interleukin-11) developed for fibrosis and oncology. First anti-IL-11 antibody to enter clinical trial in China and top tier globally. First IL-11-targeting therapeutic to enter clinical stage for pathological scarring worldwide. Also targeting idiopathic pulmonary fibrosis (IPF). Approved to initiate clinical study in China, Australia, and US. Long half-life exceeding one month. Licensed exclusively to Calico Life Sciences (Alphabet) for all regions except Greater China.
  • 7MW3711 - B7-H3 ADC Novel B7-H3 targeting antibody-drug conjugate developed by Mabwell using the IDDC™ platform. Composed of innovative antibody molecule, novel linker, and novel topoisomerase I inhibitor payload (Mtoxin™). Granted FDA Orphan Drug Designation for small cell lung cancer. Has potential applications in lung cancer, sarcoma, prostate cancer, head and neck cancer, and esophageal cancer. Phase II clinical trial ongoing.
  • 7MW4911 - CDH17 ADC ADC targeting cadherin-17 (CDH17) developed using Mabwell's proprietary IDDC™ antibody conjugation technology platform. Integrates high-specificity CDH17 monoclonal antibody with fast internalization characteristics, novel cleavable linker, and proprietary DNA topoisomerase I inhibitor MF-6 payload designed to overcome multidrug resistance. Homogeneous drug loading (DAR=4 ratio >95%) with stable plasma. IND cleared by both FDA and NMPA for advanced solid tumors and advanced colorectal/gastrointestinal cancers.

Companies that use Mabwell Biotech

Customer profile

Ideal customer profiles2 records

Mabwell Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Mabwell Biotech partnerships and signals

Strategic signal

Recent moves11 records

Expansion highlights6 records

Mabwell Biotech competitors and assessment

Company assessment

Broad incumbents

  • AstraZeneca: Global biopharmaceutical company partnering with Daiichi Sankyo on ADC franchise (Enhertu, Datopotamab Deruxtecan). AstraZeneca's ADC commercial reach and global regulatory experience represent the competitive benchmark Mabwell's Nectin-4 ADC 9MW2821 must contend with in major oncology indications.
  • Genmab: Global biotechnology company specializing in antibody therapeutics with proprietary DuoBody bispecific platform. Genmab's bispecific antibody technology and pipeline (including epcoritamab) are directly comparable to Mabwell's TCE bispecific platform approach and 6MW5311 program.
  • Hansoh Pharmaceutical: Large Chinese innovative biopharmaceutical company with HKEX listing developing oncology, psychiatry, and infectious disease therapeutics. Hansoh operates a comparable full-industry-chain business model and competes for the same Chinese biopharma talent, capital, and commercial channels as Mabwell.
  • BeiGene (BeOne Medicines): Large globally-operating Chinese biopharmaceutical company with HKEX and NASDAQ listings developing innovative oncology biologics including BRUKINSA (zanubrutinib). As a broad incumbent in the same Chinese innovative biopharma category, BeiGene's scale and global commercial infrastructure represent the standard Mabwell aspires to match.
  • Daiichi Sankyo: Global pharmaceutical leader in antibody-drug conjugates, with DXd-ADC platform powering Enhertu (HER2) and Datopotamab Deruxtecan (Trop-2). Daiichi Sankyo/AstraZeneca represent the gold-standard ADC competitor that Mabwell's IDDC™ platform must differentiate against in oncology indications.

Direct peers

  • Innovent Biologics: Leading Chinese innovative biopharmaceutical company developing oncology biologics including PD-1 inhibitors (sintilimab) and ADCs. Innovent operates a similar dual-listing model (HKEX, STAR Market) with comparable full-industry-chain R&D-to-commercialization structure and competes directly with Mabwell in China oncology biologics.
  • Henlius: Chinese biopharmaceutical company focused on biosimilars and innovative oncology biologics with HKEX listing. Henlius launched multiple biosimilars (rituximab, trastuzumab, bevacizumab, adalimumab) similar to Mabwell's MAILISHU, MAIWEIJIAN, and JUNMAIKANG biosimilars, and operates a similar global emerging-market out-licensing model.
  • Junshi Biosciences: Co-developer of Mabwell's JUNMAIKANG adalimumab biosimilar and fellow Shanghai-based innovative biopharmaceutical company. Junshi has a comparable pipeline of innovative monoclonal antibodies and bispecifics, and was co-founded by Mabwell's President of R&D Dr. Wu Hai, providing direct operational and pipeline overlap.
  • Akeso: Chinese biopharmaceutical company specializing in bispecific antibodies (e.g., cadonilimab, ivonescimab) with HKEX listing. Akeso's T-cell engagers and bispecific antibody platform are directly comparable to Mabwell's TCE bispecific platform and 6MW5311 program.
  • RemeGen: Chinese biopharmaceutical company with a directly comparable ADC and bispecific antibody pipeline. RemeGen's disitamab vedotin (RC48, Nectin-4 ADC) is the most direct competitor to Mabwell's 9MW2821, and RemeGen also operates in oncology biologics with self-developed ADC platform technology targeting similar indications (gastric, urothelial, breast).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Mabwell Biotech compliance and trust

Trust signal

Compliance6 records

Mabwell Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mabwell Biotech leadership team

Management profile

Number of profiles

Profiles12 records

Mabwell Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Mabwell Biotech funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mabwell Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mabwell Biotech

What does Mabwell Biotech do?

Mabwell Biotech is an innovation-driven biopharmaceutical company that develops, manufactures, and commercializes therapeutic biologics across oncology, immunology, bone disorders, ophthalmology, hematology, and cardiovascular disease. Its portfolio comprises antibody-drug conjugates (ADCs), bispecific and trispecific antibodies, monoclonal antibodies, and biosimilars. The company has four commercialized products (MAILISHENG/albipagrastim alfa, MAIWEIJIAN/denosumab 120mg biosimilar, MAILISHU/denosumab 60mg biosimilar, JUNMAIKANG/adalimumab biosimilar) and 10+ clinical-stage candidates built on its proprietary IDDC™ ADC platform and T-cell Engager bispecific platform.

Is Mabwell Biotech a public or private company?

Mabwell Biotech is a public company. It is classified as public and is currently operating.

When was Mabwell Biotech founded?

Mabwell Biotech was founded in 2017. It employs 101 to 250 people.

Where is Mabwell Biotech based?

Mabwell Biotech is headquartered in Shanghai, China, in the Asia region.

How does Mabwell Biotech make money?

Four revenue lines are on record. Drug Product Sales (Commercialized Products) is the primary driver. The others are international Out-licensing (License-out / NewCo), emerging Market Commercialization Partnerships and biosimilar International Supply and Royalty.

Who are Mabwell Biotech's main competitors?

Broad incumbents on record are AstraZeneca, Genmab, Hansoh Pharmaceutical, BeiGene (BeOne Medicines) and Daiichi Sankyo. Direct peers are Innovent Biologics, Henlius, Junshi Biosciences, Akeso and RemeGen.

Does Mabwell Biotech have an API?

No public API is recorded for Mabwell Biotech.

What industry is Mabwell Biotech in?

Mabwell Biotech's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MoomooMabwell Bioscience-B (02493) reported operating revenue of approximately RMB 621 million in the first three quarters, representing a year-on-year increase of 9.77%.Mabwell Biotech-B reported Q3 2026 revenue of RMB 621 million, up 9.77% year-on-year, with a net loss of RMB 678 million. Pharmaceutical sales in Q3 rose 122.13% to RMB 123 million. The company also advanced licensing and GMP certifications for its denosumab products.TradingViewMabwell (Shanghai) Bioscience: Drug sales surged, but heavy R&D and cash burn sustained substantial lossesMabwell (Shanghai) Bioscience reported 9M revenue, up 9.77% year-over-year, but losses and operating cash outflow widened due to heavy R&D investment. Drug sales more than doubled in Q3, while clinical programs advanced and overseas licensing expanded.MoomooHong Kong Stock Market Movers | Mabwell Bioscience-B (02493) rises nearly 3%; to present clinical data for 9MW2821 via oral presentation at ESMO 2026Mabwell Biotech-B shares rose nearly 3% to HK$19.37, with a turnover of HK$4.92 million. The company will present Phase II clinical trial data on its Nectin-4-targeted ADC 9MW2821 at ESMO 2026 in Madrid. Phase III trials for UC and CC are scheduled for interim analysis in 2026.The future of tradingMabwell's 9MW2821 Shows 30% Response Rate in Phase II Trial in ADC-Pretreated Triple-Negative Breast CancerMabwell announced plans to present Phase II results for its Nectin-4-targeting antibody-drug conjugate 9MW2821 at the 2026 ESMO Congress. The trial in ADC-pretreated triple-negative breast cancer showed tumor responses and disease control in 60 evaluable patients, with a manageable safety profile and no new safety signals.PRESSBEEESMO 2026 Preview .. Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer ...Middle EastMabwell will present Phase II clinical data on its Nectin-4-targeting ADC 9MW2821 at ESMO 2026. The data will cover ADC-pretreated triple-negative breast cancer patients. The company is an innovation-driven biopharmaceutical firm with a fully integrated industry chain.PR Newswire APACESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast CancerMabwell will present Phase II data on its Nectin-4-targeting ADC 9MW2821 at ESMO 2026 for ADC-pretreated triple-negative breast cancer. In 60 patients, the objective response rate was 30% and disease control rate 80%, with median progression-free survival of 3.7 months. The company plans Phase III trials for urothelial and cervical cancers.PR Newswire APACMabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer - PR Newswire APACMabwell will present Phase II data on its Nectin-4-targeting ADC 9MW2821 at ESMO 2026 for TNBC patients previously treated with a topoisomerase I ADC. Among 60 patients, the objective response rate was 30% and disease control rate 80%, with median progression-free survival of 3.7 months. The company plans Phase III trials for urothelial and cervical cancers.PR NewswireESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast CancerMabwell will present Phase II data on its Nectin-4-targeting ADC 9MW2821 at ESMO 2026 for Topo I ADC-pretreated triple-negative breast cancer. Among 60 patients, the objective response rate was 30% and disease control rate 80%, with median progression-free survival of 3.7 months. The company plans Phase III trials for urothelial and cervical cancers.Longevity.TechnologyMabwell’s antibody cuts COPD flare-ups sharplyMabwell's antibody 9MW1911, targeting ST2, reduced moderate-to-severe COPD exacerbations by 24% at 600mg and 81% at 900mg in a Phase Ib/IIa trial of 80 patients. Severe exacerbations fell 47% and 100% respectively. A larger Phase IIb study is underway, with Phase III expected in late 2026.The Pharma LetterMabwell’s 9MW1911 data support further testing of ST2 blockade in COPDMabwell Biosciences presented Phase Ib/IIa trial results for 9MW1911, an anti-ST2 monoclonal antibody, in moderate-to-severe COPD at ERS Congress 2026. The randomized, double-blind, placebo-controlled trial showed exploratory efficacy findings that were not statistically significant, but the results support further evaluation of the IL-33/ST2 pathway in COPD.